303 Phase II trial of neoadjuvant nivolumab (Nivo) and intra-tumoral (IT) CMP-001 in high-risk resectable melanoma (Neo-C-Nivo): final results
Main Authors: | Hassane Zarour, John Kirkwood, Joe-Marc Chauvin, Arivarasan Karunamurthy, Douglas Hartman, Richelle DeBlasio, Quanquan Ding, Ornella Pagliano, Amy Rose |
---|---|
Format: | Article |
Language: | English |
Published: |
BMJ Publishing Group
2020-11-01
|
Series: | Journal for ImmunoTherapy of Cancer |
Similar Items
-
Incidence rates of immune-related adverse events and their correlation with response in advanced solid tumours treated with NIVO or NIVO+IPI: a systematic review and meta-analysis
by: Puyuan Xing, et al.
Published: (2019-12-01) -
Correction: Incidence rates of immune-related adverse events and their correlation with response in advanced solid tumours treated with NIVO or NIVO+IPI: a systematic review and meta-analysis
by: Kenji Fujiwara, et al.
Published: (2020-07-01) -
A Phase 2 Study of Nivolumab Using a Fixed Dose of 40 mg (Nivo40) in Patients With Relapsed/Refractory Hodgkin Lymphoma
by: Kirill V. Lepik, et al.
Published: (2020-10-01) -
NIVO KVANTITATIVNIH PROMJENA SPECIFIČNO-MOTORIČKIH SPOSOBNOSTI NOGOMETAŠA POD UTICAJEM SITUACIONOG TRENINGA
by: Izet Bajramović, et al.
Published: (2008-08-01) -
Metastatic clear-cell renal cell carcinoma: Computed tomography texture analysis as predictive biomarkers of survival in patients treated with Nivolumab: NivoMics 01-Study
by: Z-E. Khene, et al.
Published: (2020-07-01)